PubRank

B C Y Wong

Author PubWeight™ 45.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther 2003 2.30
2 Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002 1.82
3 Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011 1.80
4 Anxiety but not depression determines health care-seeking behaviour in Chinese patients with dyspepsia and irritable bowel syndrome: a population-based study. Aliment Pharmacol Ther 2002 1.71
5 Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005 1.35
6 Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 2005 1.22
7 Histogenesis of human colorectal adenomas and hyperplastic polyps: the role of cell proliferation and crypt fission. Gut 2002 1.21
8 A validated symptoms questionnaire (Chinese GERDQ) for the diagnosis of gastro-oesophageal reflux disease in the Chinese population. Aliment Pharmacol Ther 2003 1.18
9 Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 2003 1.15
10 Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese--prevalence and spectrum of the disease. Aliment Pharmacol Ther 2002 1.14
11 Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. Aliment Pharmacol Ther 2002 1.12
12 Sequential intravenous/oral antibiotic vs. continuous intravenous antibiotic in the treatment of pyogenic liver abscess. Aliment Pharmacol Ther 2002 1.04
13 Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. Aliment Pharmacol Ther 2005 1.04
14 Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 2003 1.02
15 Onset and disappearance of reflux symptoms in a Chinese population: a 1-year follow-up study. Aliment Pharmacol Ther 2004 0.98
16 Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. Aliment Pharmacol Ther 2003 0.96
17 Positive association between gastro-oesophageal reflux disease and irritable bowel syndrome in a Chinese population. Aliment Pharmacol Ther 2007 0.91
18 Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006 0.91
19 Outcome of emergency ERCP for acute cholangitis in patients 90 years of age and older. Aliment Pharmacol Ther 2004 0.91
20 High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003 0.87
21 Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. Aliment Pharmacol Ther 2004 0.86
22 Coexistence between colorectal cancer/adenoma and coronary artery disease: results from 1382 patients. Aliment Pharmacol Ther 2006 0.86
23 A prospective comparison of performance of biopsy forceps used in single passage with multiple bites during upper endoscopy. Endoscopy 2003 0.86
24 Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. Aliment Pharmacol Ther 2003 0.85
25 Normal 24-hour ambulatory proximal and distal gastroesophageal reflux parameters in Chinese. Hong Kong Med J 2002 0.85
26 CYP2C19 genotype and the PPIs--focus on rabeprazole. J Gastroenterol Hepatol 2005 0.85
27 Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003 0.84
28 One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002 0.84
29 Validated questionnaire on diagnosis and symptom severity for functional constipation in the Chinese population. Aliment Pharmacol Ther 2005 0.83
30 Optimal serological tests for the detection of Helicobacter pylori infection in the Chinese population. Aliment Pharmacol Ther 2002 0.82
31 Review article: current management of metastatic colorectal cancer - the evolving impact of targeted drug therapies. Aliment Pharmacol Ther 2008 0.81
32 An evaluation of a rapid urine test for the diagnosis of Helicobacter pylori infection in the Chinese population. Aliment Pharmacol Ther 2002 0.81
33 Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004 0.80
34 Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2007 0.80
35 Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre. Aliment Pharmacol Ther 2007 0.80
36 Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003 0.79
37 Reduced incidence of acute graft versus host disease (GVHD) of the gut in Chinese carriers of Helicobacter pylori during allogeneic bone marrow transplantation. Ann Hematol 2003 0.79
38 The view of gastroenterologists on non-cardiac chest pain in Asia. Aliment Pharmacol Ther 2007 0.78
39 Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy. Digestion 2006 0.78
40 One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 2002 0.77
41 A rapid-release 50-mg tablet-based 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Aliment Pharmacol Ther 2003 0.77
42 Evaluation of anti-Helicobacter pylori IgG2 antibody for the diagnosis of Helicobacter pylori infection in western and Chinese populations. Aliment Pharmacol Ther 2005 0.77
43 Effects of somatostatin, octreotide and pitressin plus nitroglycerine on systemic and portal haemodynamics in the control of acute variceal bleeding. Int J Clin Pract 2002 0.76
44 Patients vote with their feet for 'On demand' rabeprazole in the maintenance treatment phase of reflux oesophagitis. Aliment Pharmacol Ther 2010 0.75
45 One size does not fit all - time to regionalize Helicobacter pylori eradication? Aliment Pharmacol Ther 2010 0.75
46 A false sense of security; symptom control does not predict healing of oesophagitis on proton pump inhibitors. Aliment Pharmacol Ther 2009 0.75
47 [Mechanism of apoptosis induced by specific COX-2 inhibitor SC236 in gastric cancer cells]. Zhonghua Zhong Liu Za Zhi 2005 0.75
48 Risk of liver cancer in patients with hepatitis B or C. Hong Kong Med J 2011 0.75